OTCM
MBGPF
Market cap52mUSD
May 29, Last price
1.05USD
Name
Moberg Pharma AB (publ)
Chart & performance
P/E
—
P/S
36.20
EPS
—
Vol. 1Y
—
Shs. 5Y
73.97%
Rev. 5Y
-16.65%
Div Yld LY
—
Div Yld TTM
—
Revenues
14m
+37.99%
Net income
-27m
L-89.32%
CFO
-17m
L+6.18%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Moberg Pharma AB (publ) functions as a pharmaceutical company, dedicated to both crafting and globally marketing medical solutions throughout Europe, the United States, and various international territories. A notable product within its development portfolio is MOB-015, a treatment designed for nail fungus, which has successfully concluded its Phase III clinical trials. Established in 2006, this enterprise is headquartered in Bromma, Sweden. It was previously known as Moberg Derma AB (publ) until its rebranding to the current name in May 2013.
Related entities
Subsidiaries
Moberg Derma Incentives AB
Key people
Jonas Ekblom
Independent Chairman of the Board · since 2025
Chief Executive Officer · since 2019
Mark Beveridge
Vice President - Finance · since 2019
Christina Erixon
Senior Director Product Management
Annica Magnusson
Senior Director Regulatory Affairs · since 2019
Richard Ding
Independent Director · since 2025
Fredrik Granstrom
Independent Director · since 2019
Independent Director · since 2025
Peter Wolpert
Independent Chairman of the Board · since 2019
Styrbjoern Zachau
Independent Director · since 2024
Headquarters & legal address
Gustavslundsvagen 42
Bromma, AB 167 51
SE
Bromma, AB 167 51
SE
Previous name
Moberg Derma AB
Previous name
Moberg Derma AB (publ)
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||